Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Canadians now have publicly funded access to CIMZIA® (certolizumab pegol) Autoinjector for the Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis indications Français


News provided by

UCB Canada Inc.

Sep 26, 2018, 06:00 ET

Share this article

Share toX

Share this article

Share toX

OAKVILLE, ON, Sept. 26, 2018 /CNW/ - UCB Canada Inc. announced today that CIMZIA® (certolizumab pegol) solution for injection in a single-use pre-filled Autoinjector is now available through public funding across Canada for the treatment of adults with moderate to severe rheumatoid arthritis, psoriatic arthritis and active ankylosing spondylitis (also a form of arthritis).

UCB is committed to providing value to patients and meeting their unique needs. As part of this commitment, they developed the CIMZIA Autoinjector for patients who prefer the convenience and ease-of-use of an automated pen. The device provides a button-free delivery system and a wide, non-slip grip that keeps patient hand disability in mind. The Autoinjector also has a large viewing window to  show the progress of the injection, and makes a clicking noise to signify both the beginning and end of the injection, giving patients confidence to know they have received their full dose of CIMZIA. UCB collaborated with OXO, a company known for thoughtful, consumer-friendly designs, to develop the technology, which was specifically designed with patients for patients.

"One in five Canadians lives with arthritis. For many, even doing everyday tasks like opening a package or taking their medication can be very difficult and painful, so how products are designed can significantly impact their quality of day-to-day life. That is why the Arthritis Society applauds UCB's commitment to designing the CIMZIA Autoinjector to be easy to use by people living with arthritis," says Bruce Watson, Director of Business and Foundation Development at the Arthritis Society, in Toronto, Ontario. "We are thrilled that UCB has put the needs of patients first when designing this innovative device, and we are thrilled at UCB's relentless commitment to improving life for people with arthritis."

About CIMZIA1
Approved in Canada in 2009, CIMZIA is referred to as a "TNF blocker." People with autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis usually have too much TNFα in their bodies, which can lead to painful and swollen joints. CIMZIA can help reduce the amount of TNFα in the body to normal levels helping to treat joint damage.

"As a clinician who treats hundreds of arthritis patients, my treatment recommendation is only as good as a patient's ability to access and adhere to medication," says Dr. Trudy Taylor, a rheumatologist in Halifax, Nova Scotia. "That's why public funding for the CIMZIA Autoinjector across Canada is important news. It finally allows more of my patients' access to an important medication with significant clinical evidence, as well as an ease-of-use delivery system that can help them address their painful and often debilitating symptoms."

About the CIMZIA Autoinjector 2
Research was conducted to ensure that the CIMZIA Autoinjector would meet the needs of patients living with autoimmune diseases like rheumatoid arthritis. A preference study was performed in 76 patients with moderate to severe rheumatoid arthritis who had no prior experience using an anti-TNF prefilled pen. The primary endpoint of the study was to assess the participants' rankings of the devices in order of preference (from one to four, where one was the most preferred), and the secondary endpoints were designed to gather patient feedback on the four devices: CIMZIA® Autoinjector®; ENBREL® SureClick®; the HUMIRA® pen; and SIMPONI® SmartJect®. Specific secondary endpoints included the comparison of the following qualities in the prefilled pens: easy to start, easy to tell when finished, easy to use and willingness to use. Overall, the results from the preference study found that the CIMZIA Autoinjector was the preferred device for the majority of patients.

Important and complete safety information about CIMZIA can be found by accessing the product monograph.

About Rheumatoid arthritis (RA)3 RA is an autoimmune disease where the body's immune system, which normally functions to protect us against infections, mistakenly attacks the lining of the joints.  The cause of this malfunctioning immune system is still unknown and while there is no cure for RA, there are some very effective medications and therapies to control the symptoms and results of the inflammation.  Inflammation in the joints causes pain, stiffness and swelling.  If this inflammation continues, it can lead to damage of the joint. The inflammation can affect other organs, such as the nerves, eyes, skin, lungs or heart.  About one out of every 100 adult Canadians has RA – about 300,000 Canadians. While anyone can get RA at any age, it affects women two to three times more often than men.  There is no cure for RA, but people who are diagnosed and treated early can avoid pain and damage to their joints and lead active and productive lives.

About Psoriatic Arthritis (PsA)4
PsA is a type of inflammatory arthritis that usually appears in people with a skin disease called psoriasis. Between 10 and 30 percent of people with psoriasis will get PsA. The disease affects both men and women in equal numbers and usually appears between the ages of 20 and 50 years. There is no cure for PsA, but with early diagnosis and appropriate treatment, patients can take control of their disease and avoid severe damage to their joints. Most people with PsA can lead active and productive lives with the help of medication, surgery (in some cases), exercise, rest and joint protection techniques.

About Ankylosing Spondylitis (AS)5
AS is a type of inflammatory arthritis that affects the spine and the sacroiliac joints that attach the pelvis to the base of the spine. 'Ankylosing' means fusing and 'spondylitis' means inflammation of the spine. As well as being a form of inflammatory arthritis, AS is also an autoimmune disease, meaning the body's own immune system attacks healthy tissue. With AS inflammation, the immune attack targets the ligaments and tendons attached to bone in the joints of the spine. The bone erodes at these sites and the body tries to repair itself by forming new bone. The bones of the spine begin to fuse, or grow together, causing the spine to become stiff, inflexible and painful. Even though new bone forms, the original bone in the spine can become thin, increasing the risk of spinal fractures. Early detection and treatment of AS can help to prevent lasting damage to the spine.  

About UCB Canada Inc.
Inspired by patients and driven by science, UCB Canada Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe autoimmune and central nervous system diseases. For more information, please consult www.ucb.com/worldwide/canada.

References

____________________________

1 CIMZIA Product Monograph. https://www.ucb-canada.ca/en/Our-Medicines/overview   Accessed September 20, 2018.

2 Domańska B, VanLunen B, Peterson L, Mountian I, Schiff M. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis. Expert Opinion on Drug Delivery 2017;4:15-22.

3 Rheumatoid arthritis. The Arthritis Society of Canada. http://www.arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/rheumatoid-arthritis Accessed May 8, 2018.

4 Psoriatic Arthritis. The Arthritis Society of Canada. http://www.arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis Accessed May 8, 2018.

5 Ankylosing Spondylitis. The Arthritis Society of Canada. http://www.arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/ankylosing-spondylitis Accessed May 8, 2018

SOURCE UCB Canada Inc.

Rebecca Krauss, Cohn & Wolfe, Tel: (416) 924-5700 ext. 4055, [email protected]; Ben Faienza, UCB Canada Inc., Tel: (905) 287-5115, [email protected]

Modal title

Organization Profile

UCB Canada Inc.

    Also from this source

  • [Pr]RYSTIGGO® Now Approved for Adults with Generalized Myasthenia Gravis (gMG) in Canada

  • BIMZELX® (bimekizumab) Negotiations with pCPA Concluded Successfully Following Positive CDA and INESSS Recommendations for Adults with Active Psoriatic Arthritis and Adults with Active Ankylosing Spondylitis

  • UCB and University Health Network (UHN) Collaborate to Enhance Axial Spondyloarthritis (axSpA) Care in Canada

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.